These findings not only provide important mechanistic insights into the effect of desloratadine on activation of autophagy-lysosome pathway, but also suggest desloratadine as a novel TFEB agonist with potential for use in the treatment of lipid metabolic disorders, such as fatty liver disease, obesity. The gene discussed is TFEB; the disease is Obesity.